idi pharma was listed on 09 October 2026 by the Deadlock ransomware group (the group's claim; Ransomware Tracker by ExposureDrift has not confirmed a breach). Deadlock listed 8 organizations that month and 115 in total.
- Listed 39 days ago.
- 1147 organizations were listed by all groups in October 2026, see the month.
- 154 in Healthcare that month.
- 24 in ES that month.
Updated 2026-11-18 07:20 UTC. Data: public leak-site listings. How we work.
Threat Group Post & Evidence
- Listed by
- Deadlock 115 listings in total
The listing states no data size and no ransom demand.
No capture of the original post
We only show a screenshot when we captured the group's own page ourselves. For this listing we have not, so none is shown.
What the group says it holds
Taken from the group's own post. Ransomware Tracker by ExposureDrift has not seen the data and cannot confirm any of this.
idi pharma is an Italian pharmaceutical company specializing in the research and development of innovative nutraceuticals and medical devices. The company focuses on formulations covered by patents and unique dosage technologies to improve patient health and quality of life (but their data leak).
Kinds of data mentioned
-
Medical or patient records
“…formulations covered by patents and unique dosage technologies to improve patient health and quality of life (but their data leak).”
-
Source code and designs
“The company focuses on formulations covered by patents and unique dosage technologies to improve patient health and quality of life (but their data…”
What to do about this listing
Choose who you are. Each step shows why it appears and, where we have one, its source. General guidance, not legal or incident-response advice.
If you work with idi pharma (customer, supplier or partner)
Within 3 days
- Do not open the group's page or download the data Do not visit the leak site or download files from a listing. Holding stolen data can be unlawful, and the files can carry malware. Wait for the company's own notice. Why: A safety rule for any leak listing.
- Ask idi pharma directly Write to your contact and ask whether your data, or your access to their systems, is in scope, and ask for a written statement. Your contract or data-protection law may oblige them to tell you if your data is affected: check the notification clause. Why: A listing is only the group's claim; the company is the one who can confirm what was taken.
- Review what idi pharma can reach of yours List the accounts, API keys, VPN or SSO connections and shared mailboxes this company has with you. Rotate the keys you gave them and remove access they do not need. Why: Access a supplier holds is how a listing about them can become a problem for you.
- Check software and integrations you take from them If you run their software or call their API, check that updates come through the usual channel and rotate the keys and tokens you hold for it. Why: The post names: source code and designs.
- If you share health data with them You may be the data controller, with notification duties of your own. Ask counsel which health-privacy rules apply to you. Why: The post names medical or health data.
Within 30 days
- Keep watching idi pharma A supplier's listing can change after the first sighting: the group can add data, change the status or publish. Add the company to your supplier list to be told, and check your own domain too. Why: A listing is a moving claim, not a single event. Add to your supplier list Check your own domain
If you are idi pharma
Within 3 days
- Handle health-data exposure Work out which patient or health records are in scope, apply the health-privacy notification rules that cover them, and prepare patient communications. Why: The post names: medical or patient records.
- Rotate secrets and signing keys Assume secrets in repositories are exposed: rotate API keys, tokens and code-signing keys, and review build and release systems for unexpected changes. Why: The post names: source code and designs.
- Check regulatory and stakeholder notification duties EU/EEA: GDPR Art. 33 and 34 require notifying the supervisory authority within 72 hours of becoming aware of a personal data breach, and affected people where risk is high. Health data adds sector rules. This is general guidance, not legal advice: confirm current rules with counsel. Why: Listing country: Spain.
General readiness for any ransomware claim (not about this listing)
- Offline, immutable backups and a restore drill Keep backups outside domain-admin reach and practise a restore; a leak does not remove the risk of re-encryption. Why: General practice for any ransomware claim; not specific to this listing.
- Look for mass file access and unusual outbound transfers Review EDR, proxy and identity logs for bulk reads, archive creation and large uploads to file-sharing services. Why: General practice for any ransomware claim; not specific to this listing.
- Phishing-resistant MFA on remote access Enforce MFA on VPN, SSO and admin panels, and retire password-only or SMS-based remote access. Why: General practice for any ransomware claim; not specific to this listing.
Listing details
Listing severity score (heuristic)
81/100 • CRITICALA heuristic built from sector, group, data volume and claim details. It is not evidence that a breach occurred or a measure of harm.
External Attack Surface Profile
ASM IntelligenceRun a free passive scan on your own domain to see what an attacker can see from the outside.